Corvus Capital Stock vs Net Invested Capital Analysis
CRVS Stock | USD 8.95 0.01 0.11% |
Corvus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Corvus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corvus Pharmaceuticals is a good investment. Please check the relationship between Corvus Pharmaceuticals Capital Stock and its Net Invested Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.
Capital Stock vs Net Invested Capital
Capital Stock vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corvus Pharmaceuticals Capital Stock account and Net Invested Capital. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Corvus Pharmaceuticals' Capital Stock and Net Invested Capital is -0.62. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Corvus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Corvus Pharmaceuticals' Capital Stock and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Corvus Pharmaceuticals are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Capital Stock i.e., Corvus Pharmaceuticals' Capital Stock and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | -0.62 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from Corvus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corvus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.At this time, Corvus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 80.6 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 7.5 M in 2024.
Corvus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Corvus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corvus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 83.6M | 85.5M | 109.5M | 68.2M | 45.6M | 68.5M | |
Other Current Liab | 6.9M | 7.6M | 7.1M | 7.5M | 2.6M | 2.5M | |
Total Current Liabilities | 12.5M | 13.4M | 12.3M | 12.1M | 6.9M | 9.7M | |
Total Stockholder Equity | 71.1M | 72.1M | 97.2M | 56.1M | 38.7M | 69.5M | |
Net Tangible Assets | 71.1M | 72.1M | 97.2M | 56.1M | 64.5M | 72.5M | |
Net Debt | (2.0M) | (14.1M) | (59.8M) | (10.6M) | (11.2M) | (11.8M) | |
Retained Earnings | (217.1M) | (223.1M) | (266.4M) | (307.7M) | (334.7M) | (318.0M) | |
Accounts Payable | 2.4M | 3.5M | 1.6M | 2.0M | 1.5M | 2.2M | |
Cash | 5.2M | 16.5M | 63.5M | 13.2M | 12.6M | 12.0M | |
Other Assets | 513K | 414K | 236K | 129K | 1.0 | 0.95 | |
Cash And Short Term Investments | 78.0M | 44.3M | 69.5M | 42.3M | 27.1M | 25.8M | |
Common Stock Shares Outstanding | 29.3M | 29.5M | 41.9M | 46.6M | 48.0M | 30.7M | |
Short Term Investments | 72.8M | 27.8M | 6.0M | 29.1M | 14.5M | 13.8M | |
Liabilities And Stockholders Equity | 83.6M | 85.5M | 109.5M | 68.2M | 45.6M | 68.5M | |
Non Current Liabilities Total | 869K | 2.3M | 1.2M | 2.6M | 1.4M | 0.0 | |
Other Current Assets | 486K | 991K | 1.3M | 728K | 744K | 687.3K | |
Other Stockholder Equity | 288.2M | 295.3M | 361.7M | 364.4M | 374.4M | 230.8M | |
Total Liab | 12.5M | 13.4M | 12.3M | 12.1M | 6.9M | 6.5M | |
Total Current Assets | 78.0M | 44.3M | 69.5M | 42.3M | 28.0M | 26.6M | |
Property Plant Equipment | 2.2M | 3.8M | 2.6M | 3.6M | 4.2M | 3.0M | |
Property Plant And Equipment Net | 2.3M | 1.6M | 3.2M | 2.2M | 1.4M | 1.8M | |
Non Current Assets Total | 5.7M | 41.3M | 40.0M | 25.9M | 17.6M | 18.0M | |
Non Currrent Assets Other | 3.3M | 2.4M | 2.5M | 1.8M | 89K | 84.6K | |
Net Receivables | 329K | 86K | 539K | 633K | 63K | 59.9K | |
Capital Surpluse | 208.4M | 280.8M | 288.2M | 295.3M | 339.6M | 233.5M | |
Inventory | (815K) | (492K) | (667K) | (735K) | (661.5K) | (694.6K) | |
Property Plant And Equipment Gross | 3.8M | 2.6M | 3.2M | 2.2M | 6.1M | 3.4M | |
Accumulated Other Comprehensive Income | 29K | 4K | 1.9M | (563K) | (967K) | (918.7K) | |
Net Invested Capital | 71.1M | 72.1M | 97.2M | 56.1M | 38.7M | 60.6M | |
Net Working Capital | 69.1M | 33.2M | 61.6M | 32.9M | 21.1M | 20.0M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.